🚀 Medial Secures Investment on Shark Tank India - Fueling the Future of Professional Social Networking. 🔥
✕
Login
Home
News
Messages
Startup Showcase
Trackers
Premium
Premium Content
Jobs
Notifications
Settings
Try our Valuation Calculator →
Log In
News on Medial
Financials, pharma, and select few lead the pack as funds turn cautious
Economic Times
·
24d ago
Medial
In June, despite gains in Nifty 50 and Nifty Smallcap 250, fund managers exercised caution, strategically investing in select financial and pharma stocks. Investments included L&T Finance, Aptus Value Housing Finance, AU Small Finance Bank, RBL Bank, and domestic pharma companies like Laurus Labs and Divi’s Laboratories. Asset management companies also showed interest in stocks like Asian Paints, Britannia, Biocon, and Infosys, indicating a selective optimism in various sectors beyond financials and pharma.
View Source
1
Related News
Which sectors will need a relook in terms of earnings projection now? Gautam Duggad explains
Economic Times
·
8d ago
Medial
Gautam Duggad of Motilal Oswal Financial Services notes that major sectors like financials and IT remain stable despite tariff impacts. Earnings growth is driven by domestic economic factors and a shift towards consumption policies. While large sectors face limited growth, smaller sectors such as EMS, cement, pharma, and consumer durables are expected to lead earnings. The performance of major sectors like banks, large-cap IT, and consumption remains modest, necessitating stock picking for better returns.
View Source
Searchlight: Emnar Pharma poised to turn around after a decline in FY23 financials
VCCircle
·
1y ago
Medial
Emnar Pharma Pvt. Ltd, a pharmaceutical company, is expected to recover in profitability for the fiscal year 2024 due to improving financial factors such as reduced debt levels and lower raw material costs. The company, specializing in API, biotech, and drug intermediaries, experienced a decline in its financials for the fiscal year 2023. However, with these improvements, it is anticipated that Emnar Pharma will see a turnaround in its financial performance.
View Source
Active ETF assets balloon. Why only a few funds dominate.
Livemint
·
1m ago
Medial
Assets in active exchange-traded funds (ETFs) are rapidly growing, driven by surging demand from investors and financial advisors. A record 660 active ETFs were launched last year, as per Broadridge Financial's report. However, only a few are likely to reach sustainable success or "escape velocity." The situation mirrors a gold rush, where a select few prosper significantly while others may not succeed, reflecting the competitive landscape of the asset management industry.
View Source
2024 to see unprecedented foreign inflows: Khemka
Livemint
·
1y ago
Medial
In an interview, Prashant Khemka, founder of WhiteOak Capital Management, believes that India might be in a favorable position for foreign investments in the coming months. He expects a massive influx of foreign money in India dedicated funds, especially if the broader emerging markets experience a positive turn. Khemka also emphasizes attractive investment opportunities in sectors like private sector financials, consumption, IT, and healthcare. He predicts stabilization and growth in the IT sector next year as global recession fears diminish.
View Source
Sensex, Nifty snap 3-day losing streak on financial, pharma boost
VCCircle
·
2m ago
Medial
India's benchmark equity indexes Sensex and Nifty ended a three-day losing streak, rising 0.5% each due to gains in pharma and financial stocks, though concerns over foreign outflows remained. All major sectors advanced, with small-caps and mid-caps rising 0.4% and 0.8%, respectively. Financials increased by 0.6% and pharma by 1.3%, alleviated by U.S. Department of Health and Human Services' comments on drug price cuts. Information technology stocks also gained, boosting overall market performance.
View Source
How to play the chaos: Traders brace for a breakout. Will Nifty hold or slip further?
Business Today
·
5m ago
Medial
Indian equities saw a downturn as the Nifty 50 closed below 22,800, primarily due to sectoral declines in Auto, Pharma, and Healthcare following Donald Trump's announcement of new tariffs on pharmaceuticals. Despite the slump, the metals sector showed resilience. Analysts suggest a persistent downtrend with key support at 22,500 and resistance between 23,000-23,200. Market sentiment remains cautious amid FII outflows, weakening currency, and global uncertainties.
View Source
Tariff woes temporary, India’s equity story still intact: Seshadri Sen
Economic Times
·
7d ago
Medial
Seshadri Sen of Emkay Global Financial Services discusses the potential impact of tariffs on India's equity market, suggesting a worst-case scenario of 25%. Despite short-term volatility and weak earnings, the long-term Indian equity story remains strong, particularly driven by cyclical recovery in consumption. Sen remains positive on consumer discretionary and industrials, while cautious about financials and FMCG sectors. He highlights internet, EMS, and airlines as strong sectors with structural growth potential.
View Source
Nifty 50 erases 2025 losses on FPI return, bargain buying
VCCircle
·
4m ago
Medial
India's Nifty 50 index reversed its year-to-date losses after a six-day rally driven by foreign portfolio investors' return and bargain hunting. It rose 1.32% to 23,658.35. The BSE Sensex also climbed 1.4% to 77,984.38. Signals of cooling inflation and increased industrial output improved market sentiment. Heavyweight financials boosted the rally, while investors remain cautious as the volatility index spiked. All major sectors gained, including key Nifty stocks Reliance and HDFC Bank.
View Source
No structural negative in Indian pharma seen, FMCG companies chasing margin: Pankaj Pandey
Economic Times
·
7d ago
Medial
Indian pharma firms focus on specialty products, despite ongoing generic drug pricing pressures. FMCG companies are now more margin-focused, with the food segment expected to grow in double digits. Structural negatives are not anticipated for Indian pharma, although the US market poses some exposure challenges. FMCG, while facing low to moderate growth, remains a potential trading option amid global sector pressures. Hotels show revenue growth, and select auto companies like Maruti and TVS display positive developments during the festive season.
View Source
Quick commerce companies slow dark stores buildout to control cash burn - The Economic Times
Economic Times
·
4d ago
Medial
Quick commerce companies are slowing down their expansion of dark stores to manage financial resources better, except for Blinkit, which plans to grow its network significantly. Other firms like Swiggy and Zepto are more cautious due to the high cost of commercial spaces. While restructuring might help improve short-term financials, it might affect competitiveness long-term as the market is poised for substantial growth. Maintaining cash reserves is emphasized for future sustainability.
View Source
Trackers
Active Indian VC’s
OG Capital
Email
With a hands-on approach, OG Capital aims to invest in over 20 promising...
Accel Partners
Email
Early and growth-stage investments in disruptive technology companies with...
Blume
Email
Early-stage venture capital firm investing in technology startups in India. Focus on...
Access All Trackers
Startup Showcase Winners
June 2025
Buddy
Helping your parents when you are miles away
BiteStop
The Pit Stop Your Cravings Deserve
Bloomer
The next generation E-commerce platform
Enter Ongoing Startup Showcase
Top Users
Trending News on Medial
Download the medial app to read full posts, comements and news.
Go to Medial App
Not Now
Know everything that’s happening in the startup ecosystem, first.
Enable Notifications?
No, thanks
Count me in
